Clinical Trial Update: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for activated CIK cells armed with a bispecific antibody in advanced liver cancer is in early status with limited disclosed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• activated CIK armed with bispecific antibody

Snippet

Sponsor: Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. | Conditions: Advanced Liver Cancer | Phase 2 | Status: UNKNOWN